RET rearrangements (RET/PTC) is a major genetic alteration in papillary thyroid carcinomas. However, the prevalence of RET/PTC differs considerably among investigators, and its impact on cancer progression has been controversial. In the current study, we applied interphase fluorescence in situ hybridization (FISH) to touch imprint cytology of 14 papillary thyroid carcinomas along with reverse-transcription polymerase chain reaction (RT-PCR) analysis. FISH DNA probes included RET locus, and PCR primers were designed targeting RET/PTC1 or RET/PTC3. Split FISH signals of RET was observed in 78.6% (11/14) of tumors. Proportions of tumor cells having split RET signals ranged from 1.8% to 19.6% (mean 9.7%) in those 11 tumors. In RT-PCR analysis, RET/PTC was found in 28.6% (4/14) of tumors. Among tumors with split RET signals, 36.4% (4/11) of tumors exhibited detectable messenger RNA of RET/PTC1 or RET/PTC3. The remaining seven tumors with split RET signals had no RET/PTCs amplicon. In conclusion, the current study disclosed that RET/PTCs occur in a small population of tumor cells in papillary thyroid carcinomas. Even though RET/PTC is a specific genetic event in the carcinomas, our results suggested the possibility of RET/PTC as "passenger" abnormalities rather than "driver" oncogenic mutation during thyroid cancer progression, warranting further studies on mechanisms and implication of RET gene instability.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00428-009-0789-8 | DOI Listing |
Discov Oncol
January 2025
Department of Clinical Laboratory, Affiliated Hospital of Guangdong Medical University, No. 57 South Renmin Avenue, Xiashan District, Zhanjiang, 524001, People's Republic of China.
Objective: Circulating protein level ratios (CPLRs) may play a crucial role in tumor progression and drug resistance by mediating interactions within the tumor microenvironment. This study aims to investigate the causal associations between CPLRs and papillary thyroid cancer (PTC), focusing on their potential implications in drug resistance mechanisms.
Methods: Genetic data for 2821 CPLRs were obtained from the GWAS and FinnGen databases.
Am J Med Genet C Semin Med Genet
January 2025
Gastrointestinal and Endocrine Tumor Unit, Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
RET gene is a driver of thyroid cancer (TC) tumorigenesis. The incidence of TC has increased worldwide in the last few decades, both in medullary and follicular-derived subtypes. Several drugs, including multikinase and selective inhibitors, have been explored.
View Article and Find Full Text PDFJ Pediatr Endocrinol Metab
January 2025
Department of Otolaryngology, Pendik Training and Research Hospital, Marmara University, Istanbul, Türkiye.
Objectives: Surgery interventions for thyroid disorders are rare in pediatric population. This study aims to present our institution's 10-year experience regarding the surgical treatment and outcomes of thyroid pathologies in children and review the literature.
Methods: All pediatric patients who underwent thyroid surgery at our institution from April 2013 to October 2023 were retrospectively reviewed.
Braz J Otorhinolaryngol
January 2025
Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Department of Head and Neck Surgery, Liaoning Province, China.
Objective: Differentiated thyroid cancers tend to excellent long-term survival after surgery. However, Locally Advanced Papillary Thyroid Cancers (LAPTCs) have poor prognosis. This study was to investigate the clinicopathologic features of LAPTC and the risk factors that affect its postoperative recurrence.
View Article and Find Full Text PDFEndocr Relat Cancer
January 2025
X Zheng, Thyroid and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Anaplastic Thyroid Cancer (ATC) is an aggressive form of cancer with poor prognosis, heavily influenced by its tumor immune microenvironment (TIME). Understanding the cellular and gene expression dynamics within the TIME is crucial for developing targeted therapies. This study analyzes the immune microenvironment of ATC and Papillary Thyroid Cancer (PTC) using single-cell RNA sequencing (scRNA-seq).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!